Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Chinese Multicenter Registry for Peutz-Jeghers Syndrome

sunnuntai 8. marraskuuta 2026 päivittänyt: Kangyu, First People's Hospital of Hangzhou

This prospective, observational patient registry will enroll approximately 1,000 individuals with a clinical or molecular diagnosis of Peutz-Jeghers syndrome (PJS) at participating hospitals in China. The registry will collect standardized clinical information, existing genetic test reports, family history, and longitudinal outcomes. The primary objective is to estimate the 10-year cumulative incidence of a first invasive malignancy after enrollment among participants without a previous malignancy or an unresolved suspected malignancy at baseline, accounting for death as a competing event. Secondary objectives address organ-specific malignancies, new primary cancers in participants with a cancer history, mortality, major polyp-related complications, and clinical and STK11 variant characteristics. Participants may be followed for up to 20 years. Biospecimen donation, additional baseline sampling, research sequencing, and patient-derived organoid studies are optional and require the corresponding consent. Refusal of an optional component does not preclude participation in the clinical registry. No treatment or clinical surveillance strategy is assigned by the study.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Peutz-Jeghersin oireyhtymä

Yksityiskohtainen kuvaus

Peutz-Jeghers syndrome is a rare inherited tumor-predisposition syndrome associated with gastrointestinal hamartomatous polyps, mucocutaneous pigmentation, and increased risks of several malignancies. This multicenter registry will document the clinical course of enrolled patients receiving usual care and will support carefully defined genotype-phenotype and translational research. It is a hospital-based, non-probability sample and is not designed to provide a probability-representative estimate for the entire Chinese PJS population.

The purpose of this study is to establish a nationwide multicenter registry of patients with PJS, integrating standardized clinical information, existing genetic reports, optional biospecimen studies and prospective follow-up. The primary objective is to estimate 10-year cumulative incidence of a first invasive malignancy among participants without previous or unresolved suspected malignancy at baseline. The study will support defined genotype-phenotype and translational analyses; it does not assign treatment or clinical surveillance.

Specific study objectives are listed below:

Establish a standardized PJS clinical database to define the clinical characteristics and natural history of the disease in Chinese patients.
Analyze the landscape of STK11 gene variants and the relationship between genotype and clinical phenotype.
Establish an optional biobank of patients with PJS, using separately consented specimens, to provide resources for approved research.
Establish separately consented patient-derived organoid models to investigate disease mechanisms and in vitro drug responses without directing patient treatment.
Explore the development of a precision management system. The workflow includes consecutive recruitment, diagnostic confirmation, core registry consent, baseline clinical-data abstraction, prospective follow-up and outcome review. Biospecimen collection, research sequencing and organoid studies are optional components; refusal does not preclude enrollment.

The registry will implement standardized baseline clinical-data abstraction, prospective follow-up and outcome review, with historical medical information will be abstracted at baseline and distinguished from prospectively observed events. All eligible, consenting participants contribute to the clinical registry. Participants will be contacted approximately every 12 months through routine visits, telephone, or institution-approved remote methods. Clinical and genetic associations will account for family relationships, recruitment pathway, center, and relevant prespecified covariates. STK11 germline variants will be classified using the ACMG/AMP framework and applicable subsequent guidance, with the reference sequence, testing scope, evidence, and interpretation date documented. Germline and tumor-only findings will be distinguished. Untested participants, participants with limited testing, those with variants of uncertain significance, and those with adequately evaluated negative findings will not be combined into a single wild-type group.

The primary analysis will estimate the cumulative incidence function at 10 years using an Aalen-Johansen approach, with uncertainty accounting for family clustering when supported by the data. Attained-age analyses will use delayed entry at enrollment and will not treat the period before enrollment as prospectively observed person-time. Optional biospecimen studies prioritize clinical residual material. No research-only tissue biopsy or enlargement of a clinical resection is permitted.Research sequencing, multi-omics, and patient-derived organoid or tumor-organoid studies will be performed only in authorized, suitable subsets. Laboratory and analytical methods will distinguish biological participants from repeated specimens or culture wells. Predictive biomarker analyses require pre-outcome specimens and family-separated validation. Research findings will not direct clinical treatment; clinically meaningful findings considered for return require appropriate confirmation, counseling, and the participant's documented preference.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

1000

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Nimi: Yu Kang
Puhelinnumero: +86 19560161853
Sähköposti: kangyu@hospital.westlake.edu.cn

Opiskelupaikat

Kiina
- - Beijing, Kiina
    - Ei vielä rekrytointia
    - Peking University Third Hospital
    - Ottaa yhteyttä:
      
      Congrong Liu
      
      Puhelinnumero: +86 13651215671
      
      Sähköposti: congrong_liu@163.com
  - Shanghai, Kiina
    - Ei vielä rekrytointia
    - Fudan University Shanghai Cancer Center
    - Ottaa yhteyttä:
      
      Yanyun Li
      
      Puhelinnumero: +86 13601903229
      
      Sähköposti: liyanyun@fudan.edu.cn
  - Shanghai, Kiina
    - Ei vielä rekrytointia
    - Obstetrics & Gynecology Hospital of Fudan University
    - Ottaa yhteyttä:
      
      Jing Xu
      
      Puhelinnumero: +86 18817301819
      
      Sähköposti: doctor_xj@163.com
  - Tianjin, Kiina
    - Ei vielä rekrytointia
    - The Second Hospital of Tianjin Medical University
    - Ottaa yhteyttä:
      
      Haitao Wang
      
      Puhelinnumero: +86 18630955984
      
      Sähköposti: peterrock2000@126.com
- Fujian
  - Fuzhou, Fujian, Kiina
    - Ei vielä rekrytointia
    - Fujian Maternity and Child Health Care Hospital
    - Ottaa yhteyttä:
      
      Huan Yi
      
      Puhelinnumero: +86 15960103922
      
      Sähköposti: yi.huan@fjmu.edu.cn
- Guangdong
  - Guangzhou, Guangdong, Kiina
    - Ei vielä rekrytointia
    - Sun Yat-sen University Cancer Center
    - Ottaa yhteyttä:
      
      Yanling Feng
      
      Puhelinnumero: +86 13925090579
      
      Sähköposti: fengyl@sysucc.org.cn
- Shandong
  - Jinan, Shandong, Kiina
    - Ei vielä rekrytointia
    - Qilu Hospital of Shandong University
    - Ottaa yhteyttä:
      
      Peng Li
      
      Puhelinnumero: +86 18560082010
      
      Sähköposti: peng_li2002@163.com
- Zhejiang
  - Hangzhou, Zhejiang, Kiina
    - Rekrytointi
    - First People's Hospital of Hangzhou
    - Ottaa yhteyttä:
      
      Yu Kang
      
      Puhelinnumero: +86 19560161853
      
      Sähköposti: kangyu@hospital.westlake.edu.cn
  - Hangzhou, Zhejiang, Kiina
    - Ei vielä rekrytointia
    - Zhejiang Cancer Hospital
    - Ottaa yhteyttä:
      
      Qiang Wen
      
      Puhelinnumero: +86 13857105097
      
      Sähköposti: wenqiang@zjcc.org.cn

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

Lapsi
Aikuinen
Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

Individuals with a confirmed clinical or molecular diagnosis of PJS who receive care at participating centers in China. Recruitment will be consecutive where feasible. Previous cancer does not preclude registry enrollment. Diagnostically unconfirmed relatives are not independently enrolled under this version. Relatives who independently meet clinical or molecular diagnostic criteria may enroll with separate consent and a unique individual identifier linked to a pedigree.

Kuvaus

Inclusion Criteria:

A clinical diagnosis of PJS meeting at least one of the following: two or more histologically confirmed Peutz-Jeghers polyps; any number of Peutz-Jeghers polyps and a family history of PJS; characteristic mucocutaneous pigmentation and a family history of PJS; or any number of Peutz-Jeghers polyps together with characteristic mucocutaneous pigmentation. Alternatively, a molecular diagnosis established by a confirmed germline pathogenic or likely pathogenic STK11 variant associated with PJS, interpreted by appropriately qualified professionals.
Valid written informed consent for the core clinical registry from the participant or the legally appropriate guardian, with age- and capacity-appropriate information and assent when applicable.
Minimum clinical or genetic documentation sufficient to confirm eligibility and agreement to at least one feasible method of longitudinal contact or record-based follow-up within the approved consent.

Biospecimen donation, availability of all specimen types, and participation in research sequencing or organoid experiments are not required for clinical registry enrollment.

Exclusion Criteria:

Neither the clinical nor molecular diagnostic pathway can be confirmed. A variant of uncertain significance alone does not satisfy molecular eligibility.
Absence of valid consent for the core registry. Duplicate records of the same individual will be merged rather than counted as additional participants. Inability or refusal to undergo an optional sample procedure is not a registry exclusion criterion. Procedure-specific safety restrictions affect that procedure only.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Havaintomallit: COHORT
Aikanäkymät: PROSPECTIVE

Kohortit ja interventiot

Ryhmä/Kohortti Ryhmä/Kohortti Ryhmä tai alaryhmä havainnointitutkimuksen osallistujia, jonka biolääketieteelliset tai terveydelliset tulokset arvioidaan.
Peutz-Jeghers syndrome Individuals meeting protocol-defined clinical diagnostic criteria or carrying a confirmed germline pathogenic or likely pathogenic STK11 variant associated with PJS. Participants with and without previous cancer may enroll. Optional biospecimen and genetic components do not determine clinical registry eligibility.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus	Toimenpiteen kuvaus	Aikaikkuna
10-year cumulative incidence of a first invasive malignancy Aikaikkuna: From enrollment to 10 years after enrollment, first invasive malignancy, death, withdrawal, or last reliable event-free assessment, as applicable.	Time from registry enrollment to the first confirmed invasive malignant neoplasm among participants with no previous malignancy and no unresolved suspected malignancy at baseline. Pathology will be the preferred evidence for solid tumors; hematologic malignancies will follow the relevant diagnostic criteria. Benign lesions, in situ disease, recurrence, progression, and metastases from an existing primary are excluded from this endpoint. The cumulative incidence at 10 years will be estimated with death before malignancy as a competing event. Participants with previous malignancy are not included in this primary risk set.	From enrollment to 10 years after enrollment, first invasive malignancy, death, withdrawal, or last reliable event-free assessment, as applicable.

Toissijaiset tulostoimenpiteet

Tulosmittaus	Toimenpiteen kuvaus	Aikaikkuna
Organ-specific cumulative incidence of a new primary invasive malignancy Aikaikkuna: From enrollment up to 20 years; estimates at 5, 10, and 20 years where supported.	First new primary invasive malignancy at each specified organ site, analyzed separately among participants without a previous malignancy at that site and with the relevant organ at risk at baseline. Site and histologic type will be recorded. Death and removal of the at-risk organ without target cancer will be handled according to the prespecified competing-risk or multistate analysis. In situ disease and metastases will not be counted as new primary invasive cancers.	From enrollment up to 20 years; estimates at 5, 10, and 20 years where supported.
Cumulative incidence of a subsequent new primary invasive malignancy in participants with a cancer history Aikaikkuna: From enrollment up to 20 years.	Time from enrollment to the next confirmed new primary invasive malignancy among participants with a malignancy diagnosed before enrollment. New primary disease will be distinguished by clinical review from recurrence, progression, and metastasis of an existing cancer. Death before a subsequent primary cancer is a competing event.	From enrollment up to 20 years.
All-cause mortality Aikaikkuna: From enrollment up to 20 years; summaries at 5, 10, and 20 years where supported.	Time from enrollment to death from any cause among all enrolled participants. Death dates and evidence sources will be recorded. Participants not known to have died will be censored at the last date on which they were known to be alive or the applicable end of follow-up. Survival probabilities and death rates will be reported.	From enrollment up to 20 years; summaries at 5, 10, and 20 years where supported.
Cumulative incidence of cancer-related death Aikaikkuna: From enrollment up to 20 years.	Time from enrollment to death attributed to malignancy, based on available medical records, death documentation, and outcome review. Non-cancer death is a competing event. Deaths of uncertain cause will be recorded separately and included in sensitivity analyses.	From enrollment up to 20 years.
Cumulative incidence of a first major polyp-related complication Aikaikkuna: From enrollment up to 20 years.	Time from enrollment to the first episode of intussusception, bowel obstruction, or gastrointestinal bleeding that results in hospitalization, emergency surgery or endoscopic treatment, or transfusion. Preventive polypectomy without an acute complication is excluded. Repeat episodes and the individual components will also be documented and summarized separately.	From enrollment up to 20 years.
Age at clinical diagnosis of PJS Aikaikkuna: At enrollment, using available historical records.	Age, in years, when the participant first met documented clinical diagnostic criteria for PJS. The evidence source and precision of the date will be recorded. Median, interquartile range, and the number with available information will be reported; molecularly ascertained participants without a clinical diagnosis will be identified separately.	At enrollment, using available historical records.
Baseline gastrointestinal polyp involvement by anatomical site Aikaikkuna: At enrollment, using available historical and baseline records.	Number and proportion of participants with documented PJS-related polyps in each gastrointestinal site before or at baseline, with sites reported separately. Each proportion will use the number with sufficient information for that site as its denominator; unassessed or unknown sites will not be coded as negative.	At enrollment, using available historical and baseline records.
Distribution of documented STK11 germline variant classifications and variant types Aikaikkuna: At enrollment; updated classifications retained separately during follow-up.	Counts and proportions of participants and independent families by STK11 germline variant classification and predefined variant type. Testing method, scope, and interpretation date will be documented. Pathogenic/likely pathogenic findings, variants of uncertain significance, adequately assessed negative findings, limited testing, and no testing will be reported separately. Genotype-phenotype association analyses use the clinical endpoints defined elsewhere and are exploratory.	At enrollment; updated classifications retained separately during follow-up.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

First People's Hospital of Hangzhou

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Sunnuntai 1. marraskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 1. lokakuuta 2046

Opintojen valmistuminen (Arvioitu)

Sunnuntai 1. lokakuuta 2056

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 16. lokakuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit